Report on Romania’s Pharmaceutical and Healthcare industry

<![CDATA[

Business Monitor International’s (BMI) Romania Pharmaceuticals and Healthcare Report (Q4 2011) provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Romania’s pharmaceuticals and healthcare industry.

BMI has revised down projections for Romania’s pharmaceutical market in 2011 to year-on-year (y-o-y) growth of +7.5% (previously +9.3%) in local currency terms, with the market worth RON12.82bn (US$4.41bn) at consumer prices. The revision is principally due to weaker than expected drug price inflation in Q211, which BMI now expects to moderate in H211.

BMI continues to expect Romania’s pharmaceutical market to return to high single-digit growth in 2011 and 2012. However, weaker than expected drug price inflation in Q211 has resulted in a downward revision of BMI’s projections. The authors continue to highlight risks in this market, especially in the delay of payments to pharmacists from the National Health Insurance House (Casa Nationala de Asigurari de Sanatate – CNAS), which is a major concern for retail pharmacies and drug producers.

Ref and Read more: http://insurancenewsnet.com/article.aspx?id=278621&type=newswires

]]>